Search results for "EMA EPAR|DISEASES|CARDIOVASCULAR DISEASES|VASCULAR DISEASES|EMOBOLISM AND THROMBOSIS" in comments (approximate match)
Showing 1 - 7 of 7 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Apixaban is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clot...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Rivaroxaban (trade name Xarelto) is an oral anticoagulant. It is the first available orally active direct factor Xa inhibitor. Upon oral administration, rivaroxaban selectively binds to both free factor Xa and factor Xa bound in the prothrombinase co...
Class:
PROTEIN
Conditions:
Desirudin (Iprivask), a recombinant hirudin, is a parenteral direct thrombin inhibitor approved to prevent venous thromboembolism in patients undergoing elective hip replacement surgery. Desirudin is a potent inhibitor of both clot-bound and freely c...
Class:
PROTEIN
Conditions:
Lepirudin is a direct thrombin inhibitor obtained by recombinant technology from the medicinal leech and used for treatment of heparin-induced thrombocytopenia (HIT). Lepirudin was the first direct thrombin inhibitor approved and most frequently used...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Edoxaban (DU-176b, trade names Savaysa, Lixiana) is a selective factor Xa inhibitor reduces thrombin generation and thrombus formation and is an orally bioavailable anticoagulant drug. It was developed by Daiichi Sankyo to reduce the risk of stroke a...
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dabigatran (Pradaxa, Prazaxa) is an anticoagulant medication that can be taken by mouth. FDA approved on October 19, 2010. Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results ...
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Fondaparinux is a synthetic and specific inhibitor of activated Factor X (Xa). By selectively binding to antithrombin III (ATIII), fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Fa...